Company profile
Respiratorius AB (publ) company profile
Respiratorius AB develops new effective drugs for cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. The company also runs a project within PET imaging with application in cardiovascular diagnostics. The company is currently conducting clinical development of a drug project (VAL-001), for the treatment of Diffust Large Cell B cell lymphoma. In COPD and asthma, Respiratorius has focused on a new class of patent-pending drug substances, which compared to existing therapies have a superior ability to relax the small airways. The substances, which utilize a new mechanism of action, have been developed via ex-vivo experiments on human lung tissue in the company's proprietary measuring and testing chamber.
Business identity
- Contact email
- [email protected]
- Phone number
- +46 70 922 41 40
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 1-10 employees
- Revenue range
- $10M-$100M
- Founded
- 1999-01-01, Year
Headquarters
- Headquarters
- Byumba, Northern Province, Rwanda
- Postal code
- 223 81
- Country code
- RW
- Continent
- Africa